© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
mutant + WT CFTR Cl channel potentiator
oral 300 mg BID , Ph. II in COPD and CF
from 1M cmpd cell-based HTS + opt.
J. Med. Chem., May 24, 2021
Millenium/Takeda, Cambridge, MA
The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.